Protagenic Therapeutics, Inc. (PTIX) financial statements (2022 and earlier)

Company profile

Business Address 149 FIFTH AVENUE
NEW YORK, NY 10010
State of Incorp. DE
Fiscal Year End December 31
SIC 7389 - Business Services, Not Elsewhere Classified (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 6717993621,6853,100
Cash and cash equivalents 6717993624003,100
Short-term investments    1,286 
Prepaid expense 20843839560
Other undisclosed current assets   250  
Total current assets: 8798426961,7803,161
Noncurrent Assets
Property, plant and equipment  0111
Total noncurrent assets:  0111
TOTAL ASSETS: 8798426971,7813,162
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 572865232136168
Accrued liabilities 142163101115
Other undisclosed accounts payable and accrued liabilities 430702222125153
Derivative instruments and hedges, liabilities 84332676426517
Total current liabilities: 6551,197908562685
Noncurrent Liabilities
Long-term debt and lease obligation 1,081175   
Long-term debt, excluding current maturities 1,081175   
Other undisclosed noncurrent liabilities 292105   
Total noncurrent liabilities: 1,374279   
Total liabilities: 2,0291,477908562685
Stockholders' equity
Stockholders' equity attributable to parent, including: (1,150)(634)(211)1,2192,477
Common stock 11111
Additional paid in capital 16,72014,68713,35812,22811,240
Accumulated other comprehensive loss (172)(172)(171)(168)(182)
Accumulated deficit (17,699)(15,150)(13,399)(10,842)(8,582)
Other undisclosed stockholders' equity attributable to parent 00000
Total stockholders' equity: (1,150)(634)(211)1,2192,477
TOTAL LIABILITIES AND EQUITY: 8798426971,7813,162

Income statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues
(Other Operating Income)
   3141
Gross profit:   3141
Operating expenses (2,552)(2,086)(2,314)(2,365)(2,234)
Other undisclosed operating loss   (3)(14)(1)
Operating loss: (2,552)(2,086)(2,314)(2,365)(2,234)
Nonoperating income (expense) 3335(243)106(42)
Foreign currency transaction loss, before tax     (7)
Other nonoperating expense (246)(13)   
Interest and debt expense  (100)  (7)
Other undisclosed income from continuing operations before equity method investments, income taxes  100  7
Net loss available to common stockholders, diluted: (2,549)(1,751)(2,558)(2,260)(2,276)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss: (2,549)(1,751)(2,558)(2,260)(2,276)
Other comprehensive income (loss)  5(6)  
Comprehensive loss: (2,549)(1,746)(2,564)(2,260)(2,276)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 1(11)414(33)
Comprehensive loss, net of tax, attributable to parent: (2,548)(1,758)(2,560)(2,246)(2,309)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: